Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Tidepool today announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors ...

Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

Abbott Laboratories (ABT) reports robust sales growth in key segments despite challenges in nutrition and diagnostics.

Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...

Abbott's optimistic forecasts due to high sales of glucose monitors; legal issues with Moderna and GSK; J&J's talc case ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Abbott’s device sales have been a bright spot as the company navigates lawsuits related to infant formula products.

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...

Abbott Laboratories has delivered a solid third quarter for 2024, with revenues hitting $10.6 billion, marking a 4.9% ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...